4:00 PM - 4:15 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 103
Hello, we are a startup company established in National Cancer Center (NCC), Korea developing anti-cancer drug. Currently we have a First-in-class candidate KN510713 targeting fatty acid oxidation as cancer specific energy metabolism. We are ready for Phase I trial to all comers and Phase II trials to PDAC patients in NCC, Korea. We are looking for foreign investment in this innovative clinical trial. I hope you can spare time to discuss about this in the meeting. Thank you.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
Korea, Republic of
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
KN510713 is about to go Phase I (under review of IND)
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2 drug candidates and 1 biomarker